TAVI vs SAVR — Low-Risk Patients
TAVI vs SAVR — Low-Risk Patients
As Years Pass, Mortality Seems to Grow Higher With TAVI vs SAVR in Low-risk Patients: Meta-analysis
• 2,644 low-risk patients: PARTNER 3 (balloon-expandable TAVI), Evolut Low Risk (self-expanding TAVI), NOTION (self-expanding TAVI).
• First year: mortality favored TAVI (HR 0.61).
• Years 5–7: mortality significantly higher with TAVI (HR 1.64).
• 7-year mortality: TAVI 26.9% vs SAVR 23.7%.
• Take-home: TAVI’s early advantage may not persist long term—important in younger, low-risk patients. Longer follow-up is needed.
Source: TCTMD | Oct 16, 2026
